[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].

CONCLUSION: Cladribine tablets are an important addition to the therapeutic landscape in RMS. With patient-friendly short dosing periods and a favorable adverse event profile, cladribine tablets provide a sustained and strong reduction of MS disease activity. The primary target population for cladribine tablets is patients with relevant MS disease activity (highly active RMS) while on first-line treatment, e. g. with injectable disease-modifying drugs.
PMID: 29523912 [PubMed - as supplied by publisher]

Source: Der Nervenarzt - March 9, 2018 Category: Neurology Authors: Meuth SG, Ruck T, Aktas O, Hartung HP Tags: Nervenarzt Source Type: research